- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00297960
Influence of Treatment With Olanzapine or Ziprasidone on Transcapillary Glucose Transport in Human Skeletal Muscle
Study Overview
Status
Conditions
Detailed Description
Background:
The efficacy of atypical antipsychotics, such as olanzapine, clozapine, risperidone, quetiapine and ziprasidone in treating a broad spectrum of symptoms in schizophrenia as well as their lower likelihood of extrapyramidal symptoms have led to an increased use of these substances. However there is an ongoing debate whether treatment with atypical antipsychotics is associated with a higher risk for metabolic abnormalities. The FDA stated in 2003 that all atypical antipsychotics increase the risk for glucose abnormalities. For olanzapine many, but not all studies report an increased risk for the development of metabolic abnormalities, such as glucose intolerance, insulin-resistance and consequentially NIDDM (Non-Insulin-Dependent-Diabetes Mellitus). Ziprasidone on the other hand seems to be associated with a more favorable metabolic safety profile.Glucose intolerance and insulin resistance being risk factors for the development of NIDDM and cardiovascular disease, the exact determination of putative effects of atypical antipsychotics on insulin sensitivity and resistance is of great need. An innovative technique, microdialysis, allows for the measurement of various analytes in the interstitial space, i.e. to assess insulin sensitivity directly at the responsible compartment, which is the human skeletal muscle. With the use of microdialysis it is possible to determine the arterial to interstitial gradient, a suitable marker for plasma glucose extraction of peripheral tissue, and thus detect insulin resistance directly at the site of insulin action.
Aim of the study:
To compare the effects of treatment with the atypical antipsychotics olanzapine and ziprasidone in steady-state conditions on the arterial to interstitial skeletal muscle gradient for glucose in human skeletal muscle during euglycaemic hyperinsulinaemic clamp conditions in male healthy volunteers.
Study design:
Open, randomized, mono-center study.
Materials and methods:
Healthy volunteers will undergo euglycaemic hyperinsulinaemic clamp and microdialysis before and after administration of 10mg olanzapine or 80mg ziprasidone during 10 days.
Study population:
15 healthy volunteers will participate in each arm of the study, summing up to a total of 30 participants.
Main outcome variable:
The arterial to interstitial skeletal muscle glucose gradient before and during euglycaemic hyperinsulinaemic clamp conditions, before and after administration of 10mg olanzapine or 80mg ziprasidone under steady-state conditions.
Study Type
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Department of Clinical Pharmacology, Medical University Vienna
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18-55
- Healthy male volunteers
- No history of drug or alcohol abuse
- No regular nicotine consumption at time of enrollment
- Physical activity at least twice a week
- Body mass Index between 19-24 kg/m2
- Normal laboratory values
- Normotension (blood pressure less than 140/90)
- No past or present history of psychiatric disorder
- No family history of diabetes or obesity
- Written informed consent
Exclusion Criteria:
- Use of medication within the last 14 days
- Consumption of alcohol within the last 5 days
- Family history of diabetes or obesity
- Past or present psychiatric disorder
Study Plan
How is the study designed?
Design Details
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Siegfried Kasper, Prof. MD, Medical University Vienna, Department of General Psychiatry
Publications and helpful links
General Publications
- Newcomer JW, Haupt DW, Fucetola R, Melson AK, Schweiger JA, Cooper BP, Selke G. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry. 2002 Apr;59(4):337-45. doi: 10.1001/archpsyc.59.4.337.
- Rosdahl H, Lind L, Millgard J, Lithell H, Ungerstedt U, Henriksson J. Effect of physiological hyperinsulinemia on blood flow and interstitial glucose concentration in human skeletal muscle and adipose tissue studied by microdialysis. Diabetes. 1998 Aug;47(8):1296-301. doi: 10.2337/diab.47.8.1296.
- Muller M, Holmang A, Andersson OK, Eichler HG, Lonnroth P. Measurement of interstitial muscle glucose and lactate concentrations during an oral glucose tolerance test. Am J Physiol. 1996 Dec;271(6 Pt 1):E1003-7. doi: 10.1152/ajpendo.1996.271.6.E1003.
Study record dates
Study Major Dates
Study Start
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Autonomic Agents
- Peripheral Nervous System Agents
- Antiemetics
- Gastrointestinal Agents
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Uptake Inhibitors
- Neurotransmitter Uptake Inhibitors
- Membrane Transport Modulators
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Olanzapine
- Ziprasidone
Other Study ID Numbers
- olanz/zipra
- EUDRACT Nr.: 2004-002147-27
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Male Volunteers
-
Shanghai Henlius BiotechRecruitingHealthy Male VolunteersChina
-
PMV Pharmaceuticals, IncCompleted
-
Hanmi Pharmaceutical Company LimitedCompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.UnknownHealthy Male VolunteersKorea, Republic of
-
Bristol-Myers SquibbCompletedHealthy Male VolunteersUnited States
-
Daewoong Pharmaceutical Co. LTD.UnknownHealthy Male VolunteersKorea, Republic of
-
Sihuan Pharmaceutical Holdings Group Ltd.CompletedHealthy Male Volunteers
-
Allist Pharmaceuticals, Inc.CompletedHealthy Male VolunteersChina
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
-
Hanlim Pharm. Co., Ltd.CompletedHealthy Male VolunteersKorea, Republic of
Clinical Trials on ziprasidone or olanzapine
-
Northwell HealthCompletedSchizophreniaUnited States
-
Beijing HuiLongGuan HospitalCompleted
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPsychotic Disorders | SchizophreniaNetherlands, Belgium
-
Pfizer's Upjohn has merged with Mylan to form Viatris...CompletedPsychotic Disorders | Schizophrenia | Schizoaffective DisorderDenmark, Iceland, Finland, Switzerland
-
Pfizer's Upjohn has merged with Mylan to form Viatris...TerminatedAcute Mania | Bipolar Disorder, ManicTurkey, Italy, Germany, Greece, Spain
-
Medical University of ViennaCompleted
-
Washington University School of MedicinePfizerCompleted
-
Eli Lilly and CompanyCompletedDepression | Schizophrenia | Schizoaffective DisorderUnited States
-
Veterans Medical Research FoundationNational Institute of Mental Health (NIMH); PfizerCompletedSchizophrenia | Insulin Resistance | Metabolic Syndrome XUnited States
-
Medical University InnsbruckCompletedPain | Fracture | Bone Density